The mission of the Ophthalmology Group is to discover and develop innovative therapies for a wide range of eye diseases. Our focus is on blinding diseases such as age-related macular degeneration, diabetic retinopathy, glaucoma, autoimmune uveitis, failed corneal grafts, and retinitis pigmentosa. With scientific expertise in innate immunity (especially the complement pathway), angiogenesis, inflammation, and vitreous and aqueous humor physiology, we are developing therapies using biologics (antibodies and antibody fragments), low molecular weight drugs, cell-based therapies, and gene therapy vectors.
Recombinant adeno-associated viral vector (rAAV)-mediated expression of RLBP1 (CRALBP) rescues the dark adaptation defect in a mouse model of RLBP1-associated retinal degeneration. Choi V, Bigelow C, McGee T, Gujar A, Li H, Hanks S, Vrouvlianis J, Dryja T, Jaffee B, Police S; Association for Research in Vision and Ophthalmology 2014, Abstract Number 835.
Generation and Characterization of LFG316, A Fully-Human Anti-C5 Antibody for the Treatment of Age-Related Macular Degeneration. Roguska M, Splawski M, Diefenbach-Streiber B, Dolan E, Etemad-Gilbertson B, Rondeau JM, Keating M; Association for Research in Vision and Ophthalmology 2014, Abstract Number 3433 - C0281.
Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, Antoni C, Draelos Z, Gold MH; Psoriasis Study Group, Durez P, Tak PP, Gomez-Reino JJ; Rheumatoid Arthritis Study Group, Foster CS, Kim RY, Samson CM, Falk NS, Chu DS, Callanan D, Nguyen QD; Uveitis Study Group, Rose K, Haider A, Di Padova F. Sci Transl Med. 2010 Oct 6, 2 (52). 52ra72. ISSN 1946-6234